Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on December 4, 2023. The report discloses a presentation made by James Martin, Chief Financial Officer and Co-Chief Executive Officer, to members of the investment community on the same date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing. The document solely references the delivery of a corporate presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing notes that the information contained in the presentation (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities under that section. Consequently, the presentation is not incorporated by reference into any other filings. No specific guidance, outlook, or risk factors are enumerated within the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of the corporate presentation (Exhibit 99.1) separately, as it is not incorporated by reference into this filing.
- Confirm that no financial data is included in this specific 8-K report.
- Note that the presentation was delivered by the Co-CEO and CFO on December 4, 2023.